Novo CEO insists ‘no change in plan’ for CagriSema launch after single-chamber device ditched

Novo Nordisk’s CEO has insisted that plans to launch the GLP-1/amylin combo treatment CagriSema remain on track, despite the pharma ending hopes of delivering the therapy in a single-chamber d Novo Nordisk’s CEO has insisted that plans to launch the GLP-1/amylin combo treatment CagriSema remain on track, despite the pharma ending work on a single-chamber delivery device. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources…

Source: FierceBiotech